Olivier Casasnovas

Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma

Pierre Vera, Emmanuel Itti, Romain Modzelewski, 2017, The Journal of Nuclear Medicine.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Catherine Thieblemont, Nicolas Mounier, Richard Delarue, 2013, The Lancet. Oncology.

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.

Martin Hutchings, Annibale Versari, Umberto Ricardi, 2018, Blood.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Andrew Lister, Anne Sonet, Hervé Tilly, 2011, The Lancet.